The Conversation (0)
ZIOPHARM Oncology announced a positive data update on the survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, their controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer.
ZIOPHARM Oncology (NASDAQ:ZIOP) announced a positive data update on the survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, their controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer.
As quoted in the press release:
This gene therapy has demonstrated a targeted, anti-tumor immune response for the treatment of recurrent glioblastoma (rGBM).
New data presented shows median overall survival (mOS) of 12.5 months has been sustained for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a longer mean follow-up time of 11.1 months as of October 18, 2017. This mOS of 12.5 months continues to compare favorably to the 5 to 8 months survival established in historical controls for patients with rGBM. Furthermore, the four patients with rGBM who received low-dose steroids maintained 100 percent survival at a mean follow-up time of 11.1 months. An anti-tumor effect was also evident with centralized review of magnetic resonance imaging (MRI) showing decreasing size of brain tumor lesions in several patients.
Additionally, data linking the intra-tumor production of hIL-12 to patients’ overall survival was presented by Francois Lebel, M.D., Chief Medical Officer of ZIOPHARM during an oral poster session, “A Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex in Adult Recurrent Glioblastoma.”
Click here to read the full press release.
Source: globenewswire.com